Evidence map›Paper›PMID 42654105›Full record

ArticlePharmaceutics2026

Comparison of Metrics for Investigating Bioequivalence in Onset of Action in Incurred Bioequivalence Studies.

Paulo Paixao, Esperanza González-Rojano, Dolores Ochoa, Francisco Abad-Santos, Manuel Roman, Víctor Mangas-Sanjuan, John Gordon, Alfredo García-Arieta

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Paulo PaixaoResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.ORCID 0000-0001-6554-4840
Esperanza González-RojanoJefatura de Docencia e Investigacion, Hospital Central de la Defensa Gomez Ulla, 28047 Madrid, Spain.
Dolores OchoaClinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria la Princesa (IIS-IP), 28006 Madrid, Spain.
Francisco Abad-SantosClinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria la Princesa (IIS-IP), 28006 Madrid, Spain.ORCID 0000-0002-6519-8885
Manuel RomanClinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria la Princesa (IIS-IP), 28006 Madrid, Spain.ORCID 0000-0002-7562-9845
Víctor Mangas-SanjuanDepartment of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, 46100 Valencia, Spain.ORCID 0000-0002-3388-5023
John GordonDivision of Biopharmaceutics Evaluation, Bureau of Pharmaceutical Sciences, Therapeutic Products Directorate, Health Canada, Ottawa, ON K1A 0K9, Canada.
Alfredo García-ArietaDivision of Pharmacology and Clinical Evaluation, Department of Human Use Medicines, Spanish Agency for Medicines and Health Care Products, 28022 Madrid, Spain.ORCID 0000-0002-9702-6973

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

absorption constantbioequivalenceinterceptonset of actionpartial area under the curve until the median tmax of the referencepartial area under the curve until the tmax of the reference in each subjecttime of maximum concentration

Identifiers

PMID42654105
PMCPMC13516050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.